Thus, it is not surprising that, as supported by preclinical models in prostate cancer models, several ongoing clinical trials are evaluating Abiraterone or Enzalutamide in association with different PI3K inhibitors [259,260]. This evidence concerns the gene PIK3CA and prostate cancer.